Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC Exosomes for Trigeminal Neuralgia and Peripheral Neuropathy
NCT05152368Phase 1Recruiting
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Start
- Sep 2022
- Primary completion
- Jan 2028
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of mesenchymal stem cell exosomes in trigeminal neuralgia (TN) and peripheral neuropathy, sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Primary endpoint: Adverse Events at 4 years. Started Sep 2022; status: recruiting.
02
Drugs
mesenchymal stem cell exosomes
03
Conditions
trigeminal neuralgia (TN)peripheral neuropathy
Beyond the preview
Go deeper on NCT05152368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05152368.